The second-generation Chevrolet Bolt is expected to drop for the 2027 model year. This new generation is more of a refresh than a complete redesign, but there's at least one major difference. The ...

According to the Chevy Bolt EV’s executive chief engineer, stretching production past 18 months is possible, at least in theory. 2027 Chevrolet Bolt EV’s production run is set for only 18 months.

Production of the 2027 Chevy Bolt has been under way since December, and more than 3,000 units have arrived on dealer lots or are in transit. However, EV shoppers couldn’t get their hands on a ...

The 2027 Chevy Bolt is back in showrooms, but buyers hoping for hands-free driving will need to wait a bit longer. Although the reborn electric hatch-crossover already touts upgraded tech, faster ...

Chevrolet reintroduced the affordable Bolt last year, but the company’s production timeline shows it’ll only stick around for about 18 months. The Chevrolet Bolt will end production in 2028 after a ...

The last time we saw the Chevrolet Bolt, the littlest Chevy EV could manage just over 250 miles of range when fully charged. Considering the competition at the time, it was a pretty impressive number ...

The Chevrolet Bolt was meant to be GM’s answer to affordable EVs aimed at ushering mainstream drivers into the electric era. Instead, it became a cautionary tale, plagued by multiple battery-related ...

LOS ANGELES (KABC) -- This might sound familiar: Chevrolet is coming out with a new electric car called the Bolt. Okay, technically they're bringing back the Bolt for 2027, after it was dropped a ...

The Chevrolet Bolt was one of the earliest electric vehicles to offer well over 200 miles (321 km) of range at a competitive price. For Ars, it was love at first drive, and that remained true from ...

The new Bolt will start under $30,000, which should make it a welcome addition to the stubbornly expensive EV market in the US. The new Bolt will start under $30,000, which should make it a welcome ...

Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy. The company had previously been expecting initial ...